References
Cannon, M.J., Schmid, D.S., and Hyde, T.B. (2010). Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20, 202-213.
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., and Dou, Q.P. (2011). Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets11, 239-253.
Chui, A.J., Okondo, M.C., Rao, S.D., Gai, K., Griswold, A.R., Johnson, D.C., Ball, D.P., Taabazuing, C.Y., Orth, E.L., Vittimberga, B.A., and Bachovchin, D.A. (2019). N-terminal degradation activates the NLRP1B inflammasome. Science 364, 82-85.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26,1367-1372.
Dolan, A., Cunningham, C., Hector, R.D., Hassan-Walker, A.F., Lee, L., Addison, C., Dargan, D.J., Mcgeoch, D.J., Gatherer, D., Emery, V.C., Griffiths, P.D., Sinzger, C., Mcsharry, B.P., Wilkinson, G.W.G., and Davison, A.J. (2004). Genetic content of wild-type human cytomegalovirus. J Gen Virol 85, 1301-1312.
El Helou, G., and Razonable, R.R. (2019). Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist 12, 1481-1491.
Fielding, C.A., Aicheler, R., Stanton, R.J., Wang, E.C., Han, S., Seirafian, S., Davies, J., Mcsharry, B.P., Weekes, M.P., Antrobus, P.R., Prod’homme, V., Blanchet, F.P., Sugrue, D., Cuff, S., Roberts, D., Davison, A.J., Lehner, P.J., Wilkinson, G.W., and Tomasec, P. (2014). Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog 10, e1004058.
Fielding, C.A., Weekes, M.P., Nobre, L.V., Ruckova, E., Wilkie, G.S., Paulo, J.A., Chang, C., Suárez, N.M., Davies, J.A., Antrobus, R., Stanton, R.J., Aicheler, R.J., Nichols, H., Vojtesek, B., Trowsdale, J., Davison, A.J., Gygi, S.P., Tomasec, P., Lehner, P.J., and Wilkinson, G.W. (2017). Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. Elife6.
Goodwin, C.M., Ciesla, J.H., and Munger, J. (2018). Who’s Driving? Human Cytomegalovirus, Interferon, and NFκB Signaling. Viruses 10.
Griffiths, P., Baraniak, I., and Reeves, M. (2015). The pathogenesis of human cytomegalovirus. J Pathol 235, 288-297.
Halenius, A., Gerke, C., and Hengel, H. (2015). Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver? Cell Mol Immunol 12, 139-153.
Hsu, J.L., Van Den Boomen, D.J., Tomasec, P., Weekes, M.P., Antrobus, R., Stanton, R.J., Ruckova, E., Sugrue, D., Wilkie, G.S., Davison, A.J., Wilkinson, G.W., and Lehner, P.J. (2015). Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141. PLoS Pathog 11, e1004811.
Jackson, S.E., Mason, G.M., and Wills, M.R. (2011). Human cytomegalovirus immunity and immune evasion. Virus Res157, 151-160.
Kim, Y.E., Lee, J.H., Kim, E.T., Shin, H.J., Gu, S.Y., Seol, H.S., Ling, P.D., Lee, C.H., and Ahn, J.H. (2011). Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression. J Virol 85, 11928-11937.
Kisselev, A.F., and Goldberg, A.L. (2001). Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8, 739-758.
Le-Trilling, V.T., and Trilling, M. (2015). Attack, parry and riposte: molecular fencing between the innate immune system and human herpesviruses. Tissue Antigens 86, 1-13.
Manicklal, S., Emery, V.C., Lazzarotto, T., Boppana, S.B., and Gupta, R.K. (2013). The ”silent” global burden of congenital cytomegalovirus.Clin Microbiol Rev 26, 86-102.
Nathans, R., Cao, H., Sharova, N., Ali, A., Sharkey, M., Stranska, R., Stevenson, M., and Rana, T.M. (2008). Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26, 1187-1192.
Nightingale, K., Lin, K.M., Ravenhill, B.J., Davies, C., Nobre, L., Fielding, C.A., Ruckova, E., Fletcher-Etherington, A., Soday, L., Nichols, H., Sugrue, D., Wang, E.C.Y., Moreno, P., Umrania, Y., Huttlin, E.L., Antrobus, R., Davison, A.J., Wilkinson, G.W.G., Stanton, R.J., Tomasec, P., and Weekes, M.P. (2018). High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms. Cell Host Microbe24, 447-460.e411.
Nobre, L.V., Nightingale, K., Ravenhill, B.J., Antrobus, R., Soday, L., Nichols, J., Davies, J.A., Seirafian, S., Wang, E.C., Davison, A.J., Wilkinson, G.W., Stanton, R.J., Huttlin, E.L., and Weekes, M.P. (2019). Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions. Elife 8.
Patel, M., Vlahava, V.M., Forbes, S.K., Fielding, C.A., Stanton, R.J., and Wang, E.C.Y. (2018). HCMV-Encoded NK Modulators: Lessons From in vitro and in vivo Genetic Variation. Front Immunol 9,2214.
Price, C.T., Al-Quadan, T., Santic, M., Rosenshine, I., and Abu Kwaik, Y. (2011). Host proteasomal degradation generates amino acids essential for intracellular bacterial growth. Science 334,1553-1557.
Reeves, M.B., Macary, P.A., Lehner, P.J., Sissons, J.G., and Sinclair, J.H. (2005). Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci U S A 102, 4140-4145.
Schreiner, S., and Wodrich, H. (2013). Virion factors that target Daxx to overcome intrinsic immunity. J Virol 87, 10412-10422.
Sloan, E., Orr, A., and Everett, R.D. (2016). MORC3, a Component of PML Nuclear Bodies, Has a Role in Restricting Herpes Simplex Virus 1 and Human Cytomegalovirus. J Virol 90, 8621-8633.
Stanton, R.J., Baluchova, K., Dargan, D.J., Cunningham, C., Sheehy, O., Seirafian, S., Mcsharry, B.P., Neale, M.L., Davies, J.A., Tomasec, P., Davison, A.J., and Wilkinson, G.W. (2010). Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120,3191-3208.
Tanaka, J., Ogura, T., Kamiya, S., Sato, H., Yoshie, T., Ogura, H., and Hatano, M. (1984). Enhanced replication of human cytomegalovirus in human fibroblasts treated with dexamethasone. J Gen Virol 65 ( Pt 10), 1759-1767.
Tavalai, N., Adler, M., Scherer, M., Riedl, Y., and Stamminger, T. (2011). Evidence for a dual antiviral role of the major nuclear domain 10 component Sp100 during the immediate-early and late phases of the human cytomegalovirus replication cycle. J Virol 85,9447-9458.
Tran, K., Kamil, J.P., Coen, D.M., and Spector, D.H. (2010). Inactivation and disassembly of the anaphase-promoting complex during human cytomegalovirus infection is associated with degradation of the APC5 and APC4 subunits and does not require UL97-mediated phosphorylation of Cdh1. J Virol 84, 10832-10843.
Weekes, M.P., Tan, S.Y., Poole, E., Talbot, S., Antrobus, R., Smith, D.L., Montag, C., Gygi, S.P., Sinclair, J.H., and Lehner, P.J. (2013). Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 340,199-202.
Weekes, M.P., Tomasec, P., Huttlin, E.L., Fielding, C.A., Nusinow, D., Stanton, R.J., Wang, E.C.Y., Aicheler, R., Murrell, I., Wilkinson, G.W.G., Lehner, P.J., and Gygi, S.P. (2014). Quantitative temporal viromics: an approach to investigate host-pathogen interaction.Cell 157, 1460-1472.
Wiertz, E.J., Jones, T.R., Sun, L., Bogyo, M., Geuze, H.J., and Ploegh, H.L. (1996). The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol.Cell 84, 769-779.